New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 19, 2014
07:09 EDTSLXPSalix risk/reward favorable ahead of trial, says Stifel
Stifel is comfortable owning Salix ahead of the expected release of TARGET-3 retreatment data for Xifaxan in diarrhea-related IBS in coming weeks. The firm thinks the stock could rise significantly if the data is positive, while a decline in shares on negative results would create a buying opportunity. The firm thinks there is a 65%-70% chance that the data will be positive, and it estimates that the stock could climb up to 20%-25% on positive data. It keeps a Buy rating on the stock.
News For SLXP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
12:34 EDTSLXPSalix mentioned as a potential acquisition target by dealReporter
November 14, 2014
10:00 EDTSLXPOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:03 EDTSLXPSalix upgraded to Buy from Neutral at UBS
UBS upgraded Salix Pharmaceuticals to Buy saying it believes management has a better handle on inventory levels than investors think. The sees opportunity at current share levels and lowered its price target for shares to $116 from $160.
November 11, 2014
08:20 EDTSLXPSalix risk/reward remains favorable, says Leerink
Subscribe for More Information
06:14 EDTSLXPSalix risk/reward now 'more interesting,' says Deutsche Bank
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use